ImmunAlp PDF Print E-mail


The process of identifying compounds with toxic properties in the early stages of drug development is an essential step in avoiding wasting valuable time and money on unsuitable and usafe drug candidates.

The ImmunAlp website is currently under construction. Please refer to this webpage until further notice.

Please take part in our survey by clicking here and help us ensure we meet the demands of Industry in the field of immunotoxicity.


image_cp_immunalpWithin this context, the goal of the ImmunAlp technology platform is to address the need for suitable testing methods to predict immune response and/or the toxicity of drugs, chemicals and cosmetic compounds.

ImmunAlp's approach is to implement a global analysis of the immune system and its deviations in chronic diseases associated with inflammation or exposure to toxic agents. ImmunAlp contributes to the development and the validation of innovation in the field of immune assays.

The exploration of these fundamental mechanisms provides immunological parameters which are used in the development of therapeutic trials based on the activation of the immune system (vaccines, immune therapies) as well as the evaluation of risk (immunotoxicity, exotoxicity).

The ImmunAlp Offering

logo_immunalpActivation of the immune systemimage5

  • Complement activation
  • Dose/Response tests for secretion of cytokines / chemokines
  • Functional test of immune cells (dendritic cells, lymphocytes, NK cells, etc.)


  • Analysis of cells involved in immune response in blood and tissues
  • Gene expression
  • Protein / peptide interactions
  • Identification of the specificity of the immune response: antibodies and T Cell receptors


  • Cytokines / chemokines production
  • Immune Cell characterization (eg, CBC, Flow Cytometry, Immunohistochem.)
  • Antibodies and Antigens in body fluids


  • Dose/Response tests for cell mortality, aplasia, cell features
  • Distribution of nanoparticles or agents in the cells
  • Quantification of endocytosis and retention
  • Effects of the agent or nanoparticles on the functions of immune cells or tissues


  • Ability to produce biological material (cells, transfectants etc.)

Key Benefitsimage3

  • A wide range of cost-efficient customised services
  • Multidisciplinary approach helps give holistic answers to problems
  • Expertise in the short and long term effects of immunotoxicology
  • Risk identification and development of best practice/industrial regulations
  • R&D of innovative assays

Technological Infrastructure

logo_immunalpGene expression quantification

  • real time PCR 96 and 480 wells (Light Cyber 480 Roche, BioRad FX96)
  • DNA Analyzer (310 Genetic Analyzer, Applied Biosystem)

logo_immunalpSystem for molecular detection in real-time imaging of surface plasmon resonance (iSPR)

  • Arrayer (OmniGrid Micro, Genomic Solutions)
  • iSPR systems (BioPlex et LabPlex, GenOptics)


  • Automated microplate processor ELISA (Evolis, BioRad)
  • Multi label counter ELISA (Perkin Elmer)

logo_immunalpFlow cytometry and cell sorting

  • Analyzer 13 parameters, 4 lasers (LSR-II, Becton Dickinson) and 6 parameters, 2 lasers (Accuri C6)
  • FACS cell sorting 9 parameters, 3 lasers (Aria, Becton Dickinson)
  • Magnetic Beads cell sorting (Miltenyi)

logo_immunalpAccess to cell culture, animal facilities, fluorescence confocal microscopy, protein analysis


  • Diseases: infections, cancers, immune dysfunctions: chronic inflammation, auto-immunity, allergy
  • Treatments: vaccines, grafts, implants, vectors


  • Immuno-toxicity of materials, nanoparticles and natural molecules or engineered


  • Supplements and nutraceuticals

At a Glance


  • Interactions with complement and cells (lymphocytes, dendritic and endothelial cells)
  • Evaluation of inflammatory and immune responses


Arrays for molecular interactions in the serum or other biological fluids (SPRi)

  • Serology: antibodies or antigens
  • Receptors / Ligands


Arrays for cell interactions in the blood or tissues (SPRi, Fluorescence)

  • Cell characterization: makers, types
  • Cell functions monitoring



Scientific Director
Patrice MARCHE

Valentine PANEL, Ph.D
ImmunAlp Platform Manager
Tel. +33 (0)4 56 00 60 42
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Download the brochure here




“We are convinced of the usefulness of BGENE’s customized sequence modification service on bacterial genomes or vectors without scarring"  European biotech company